Effectiveness and Safety of Colloidal Dispersion of Amphotericin B for Treating Mucormycosis: Insights from Real-World Data
-
By
-
Ying-Kui Jiang
-
Wen-Jia Qiu
-
Yun Cao
-
Jun-Tian Huang
-
Rong-Sheng Zhu
-
Ling-Hong Zhou
-
Hua-Zhen Zhao
-
Jie Tong
-
Zhong-Qing Chen
-
Li-Ping Zhu
-
February 10, 2026
-
Clinical Scorecard: Effectiveness and Safety of Colloidal Dispersion of Amphotericin B for Treating Mucormycosis: Insights from Real-World Data
At a Glance
| Category | Detail |
|---|
| Condition | Mucormycosis |
| Key Mechanisms | Caused by fungi in the order Mucorales, characterized by tissue necrosis and vascular thrombosis. |
| Target Population | Patients with uncontrolled diabetes, iatrogenic immunosuppression, or trauma. |
| Care Setting | Tertiary care hospitals. |
Key Highlights
- Amphotericin B (AmB) is the mainstay of treatment for mucormycosis.
- ABCD has improved accessibility and affordability in China since its approval.
- Liposomal amphotericin B (L-AmB) is recommended as first-line treatment.
- Surgical debridement is recommended to improve survival rates.
- COVID-19 has increased the prevalence of mucormycosis.
Guideline-Based Recommendations
Diagnosis
- Diagnosis based on EORTC/MSGERC consensus definitions.
Management
- First-line treatment with L-AmB at 5–10 mg/kg/day; ABCD recommended at 3–4 mg/kg/day.
Monitoring & Follow-up
- Assess response to treatment based on survival, clinical symptoms, and mycological evidence.
Risks
- Delayed treatment increases mortality; AmB-d is not recommended due to toxicity.
Patient & Prescribing Data
38 adult patients with proven, probable, or possible mucormycosis.
ABCD prescribed at physician discretion; dexamethasone used as preventive medication.
Clinical Best Practices
- Combine antifungal therapy with surgical debridement.
- Monitor for adverse drug reactions (ADRs) during treatment.
References